Biltricide
What is this? Biltricide is a medicine with praziquantel. It treats infections caused by flukes (tiny worms).
What's happening? There is less Biltricide available now. Other similar medicines can be used instead.
Does this affect me? If you take Biltricide, your supply may be limited. Ask your doctor or pharmacist for help.
What should I do? Do not stop taking your medicine without advice. Talk to your pharmacist or doctor about other options.
🤖 To jest automatycznie generowane streszczenie w języku prostym na podstawie oficjalnego komunikatu agencji, przy użyciu AI. Ma charakter wyłącznie informacyjny — nie stanowi porady medycznej. W kwestiach dotyczących Twojego zdrowia zawsze konsultuj się z farmaceutą lub lekarzem oraz zapoznaj się z oficjalnym źródłem zamieszczonym poniżej.
📋 Z oficjalnego komunikatu organu
Zaktualizowano 1 tydzień temu- Pierwsza publikacja
- 26/08/2025
- Leki objęte
- Biltricide
- Słabości dotknięte
- 600 mg film-coated tablets
- Status niedoboru
- Ongoing
- Obszar terapeutyczny (MeSH)
- Trematode Infections
- Początek niedoboru dostaw
- 26/08/2025
- Dostępność alternatyw
- Yes
- Międzynarodowa niezastrzeżona nazwa (INN) lub nazwa powszechna
- praziquantel
Zawartość strony
Braki w dostawie
There is a shortage of Biltricide in the European Union/European Economic Area (EU/EEA).
Biltricide contains the active substance praziquantel and is used for the treatment of infections caused by trematodes (parasitic worms).
The company informed EMA that it is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine. This has led to a shortage of Biltricide in the EU.
The shortage is not related to a quality defect of the product or a safety issue.
The shortage affects all Member States where the product is marketed: Germany, France and the Netherlands. Other countries that import Biltricide are also affected.
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - Working Party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
The SPOC Working Party supports the MSSG and monitors and reports events that could affect the supply of medicines in the EU.
- The company that markets Biltricide is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine in the EU. This has led to a shortage of the medicine in the EU.
- For patients with a trematode infection other than schistosomiasis, healthcare professionals should consider alternative treatment options.
- For patients with schistosomiasis, there is no other effective treatment available in the EU. Healthcare professionals should consult local or national guidelines on how to manage these patients.
- For additional information consult your country’s shortage register or contact your national competent authority.
- The company that markets Biltricide, a medicine used to treat certain parasitic (worm) infections, is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine in the EU.
- Other treatments are available for most parasitic infections; your doctor will discuss with you the best alternative treatment option.
- There is no treatment alternative for schistosomiasis in the EU; your doctor will manage your condition in line with relevant guidelines.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Powód niedoboru
The company informed EMA that it is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine. This has led to a shortage of Biltricide in the EU.
The shortage is not related to a quality defect of the product or a safety issue.
Państwa członkowskie objęte
The shortage affects all Member States where the product is marketed: Germany, France and the Netherlands. Other countries that import Biltricide are also affected.
Monitorowanie niedoborów
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - Working Party) are closely monitoring the supply situation and engaging with the marketing authorisation holder to mitigate the impact of the supply shortage.
The SPOC Working Party supports the MSSG and monitors and reports events that could affect the supply of medicines in the EU.
Zalecenia dla pracowników służby zdrowia
- The company that markets Biltricide is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine in the EU. This has led to a shortage of the medicine in the EU.
- For patients with a trematode infection other than schistosomiasis, healthcare professionals should consider alternative treatment options.
- For patients with schistosomiasis, there is no other effective treatment available in the EU. Healthcare professionals should consult local or national guidelines on how to manage these patients.
- For additional information consult your country’s shortage register or contact your national competent authority.
Zalecenia dla pacjentów i opiekunów
- The company that markets Biltricide, a medicine used to treat certain parasitic (worm) infections, is no longer able to manufacture Biltricide for commercial reasons and will stop marketing the medicine in the EU.
- Other treatments are available for most parasitic infections; your doctor will discuss with you the best alternative treatment option.
- There is no treatment alternative for schistosomiasis in the EU; your doctor will manage your condition in line with relevant guidelines.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Kluczowe informacje
- Medicines affected
- Biltricide
- Supply shortage status
- Ongoing
- International non-proprietary name (INN) or common name
- praziquantel
- Therapeutic area (MESH)
- Trematode Infections
- Strengths affected
- 600 mg film-coated tablets
- Availability of alternatives
- Yes
Kluczowe daty
- Start of supply shortage
- First published
Informacje dotyczące medycyny
🔬 Szczegóły medyczne / techniczne dla specjalistów
INN: praziquantel · Strengths: 600 mg film-coated tablets · Area: Trematode Infections · Alternatives: Yes
Wszystkie informacje na tej stronie pochodzą z oficjalnego komunikatu agencji. Tłumaczymy i podsumowujemy je; nie dodajemy ani nie zmieniamy faktów.
